The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir
Abstract
Antagonists of the human immunodeficiency virus type 1 (HIV-1) coreceptor, CCR5, are being developed as the first anti-HIV agents acting on a host cell target. We monitored the coreceptor tropism of circulating virus, screened at baseline for coreceptor tropism, in 64 HIV-1-infected patients who received maraviroc (MVC, UK-427,857) as monotherapy for 10 days. Sixty-two patients harbored CCR5-tropic virus at baseline and had a posttreatment phenotype result. Circulating virus remained CCR5 tropic in 60/62 patients, 51 of whom experienced an HIV RNA reduction from baseline of >1 log 10 copies/ml, indicating that CXCR4-using variants were not rapidly selected despite CCR5-specific drug pressure. In two patients, viral load declined during treatment and CXCR4-using virus was detected at day 11. No pretreatment factor predicted the emergence of CXCR4-tropic virus during maraviroc therapy in these two patients. Phylogenetic analysis of envelope ( Env ) clones from pre- and posttreatment time points indicated that the CXCR4-using variants probably emerged by outgrowth of a pretreatment CXCR4-using reservoir, rather than via coreceptor switch of a CCR5-tropic clone under selection pressure from maraviroc. Phylogenetic analysis was also performed on Env clones from a third patient harboring CXCR4-using virus prior to treatment. This patient was enrolled due to a sample labeling error. Although this patient experienced no overall reduction in viral load in response to treatment, the CCR5-tropic components of the circulating virus did appear to be suppressed while receiving maraviroc as monotherapy. Importantly, in all three patients, circulating virus reverted to predominantly CCR5 tropic following cessation of maraviroc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
Dean, M., Carrington, M., Winkler, C., Huttley, G. A., Smith, M. W., Allikmets, R., Goedert, J. J., Buchbinder, S. P., Vittinghoff, E., Gomperts, E., et al. (1996) · Science · doi:10.1126/science.273.5283.1856 · Cited by 2,484
[22] Using CLUSTAL for multiple sequence alignments
Higgins, D. G., Thompson, J. D., & Gibson, T. J. (1996) · Methods in Enzymology · doi:10.1016/s0076-6879(96)66024-8 · Cited by 1,571
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Self-citationThe HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes
Bleul, C. C., Wu, L., Hoxie, J. A., Springer, T. A., & Mackay, C. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1925 · Cited by 1,134
Shankarappa, R., Margolick, J. B., Gange, S. J., Rodrigo, A. G., Upchurch, D., Farzadegan, H., Gupta, P., Rinaldo, C. R., Learn, G. H., He, X., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.12.10489-10502.1999 · Cited by 926 · cited 2×
“In contrast, CXCR4using virus tends to emerge in the later stages of the infection in around 60% of progressing patients and its emergence coincides with an accelerated disease progression (22, 23, 32, 36).”
BackgroundEnfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035026 · Cited by 914
A new classification for HIV-1
Berger, E. A., Doms, R. W., Fenyö, E.-M., Korber, B. T. M., Littman, D. R., Moore, J. P., Sattentau, Q. J., Schuitemaker, H., Sodroski, J., & Weiss, R. A. (1998) · Nature · doi:10.1038/34571 · Cited by 830
Koot, M., Keet, I. P. M., Vos, A. H. V., de Goede, R. E. Y., Roos, M. T. L., Coutinho, R. A., Miedema, F., Schellekens, P. T. A., & Tersmette, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-9-199305010-00004 · Cited by 785
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arastéh, K., Nelson, M., Katlama, C., Stellbrink, H.-J., Delfraissy, J.-F., Lange, J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035211 · Cited by 656
T Cell Dynamics in HIV-1 Infection
Douek, D. C., Picker, L. J., & Koup, R. A. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141053 · Cited by 571
De Jong, J. J., De Ronde, A., Keulen, W., Tersmette, M., & Goudsmit, J. (1992) · Journal of Virology · doi:10.1128/jvi.66.11.6777-6780.1992 · Cited by 505
Hendrix, C. W., Flexner, C., MacFarland, R. T., Giandomenico, C., Fuchs, E. J., Redpath, E., Bridger, G., & Henson, G. W. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1667-1673.2000 · Cited by 504
Fätkenheuer, G., Pozniak, A. L., Johnson, M. A., Plettenberg, A., Staszewski, S., Hoepelman, A. I. M., Saag, M. S., Goebel, F. D., Rockstroh, J. K., Dezube, B. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1319 · Cited by 495
Self-citationMoore, J. P., Kitchen, S. G., Pugach, P., & Zack, J. A. (2004) · AIDS Research and Human Retroviruses · doi:10.1089/088922204322749567 · Cited by 494
Jensen, M. A., Li, F.-S., van ’t Wout, A. B., Nickle, D. C., Shriner, D., He, H.-X., McLaughlin, S., Shankarappa, R., Margolick, J. B., & Mullins, J. I. (2003) · Journal of Virology · doi:10.1128/jvi.77.24.13376-13388.2003 · Cited by 428
Brumme, Z. L., Goodrich, J., Mayer, H. B., Brumme, C. J., Henrick, B. M., Wynhoven, B., Asselin, J. J., Cheung, P. K., Hogg, R. S., Montaner, J. S. G., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/431519 · Cited by 270
Eugen-Olsen, J., Iversen, A. K. N., Garred, P., Koppelhus, U., Pedersen, C., Benfield, T. L., Sorensen, A. M., Katzenstein, T., Dickmeiss, E., Gerstoft, J., et al. (1997) · AIDS · doi:10.1097/00002030-199703110-00007 · Cited by 234
Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV‐1 Infection
Moyle, G. J., Wildfire, A., Mandalia, S., Mayer, H., Goodrich, J., Whitcomb, J., & Gazzard, B. G. (2005) · The Journal of Infectious Diseases · doi:10.1086/428096 · Cited by 230
Self-citationNew anti‐HIV agents and targets
Clercq, E. D. (2002) · Medicinal Research Reviews · doi:10.1002/med.10021 · Cited by 214
Resch, W., Hoffman, N., & Swanstrom, R. (2001) · Virology · doi:10.1006/viro.2001.1087 · Cited by 202
Hoffman, N. G., Seillier-Moiseiwitsch, F., Ahn, J., Walker, J. M., & Swanstrom, R. (2002) · Journal of Virology · doi:10.1128/jvi.76.8.3852-3864.2002 · Cited by 170
Assessing chemokine co-receptor usage in HIV
Coakley, E. P. G., Petropoulos, C. J., & Whitcomb, J. M. (2005) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200502000-00003 · Cited by 151
Self-citationMeyer, L., Magierowska, M., Hubert, J., Rouzioux, C., Deveau, C., Sanson, F., Debré, P., Delfraissy, J., & Theodorou, I. D. (1997) · AIDS · doi:10.1097/00002030-199711000-00001 · Cited by 143
Intrinsic Obstacles to Human Immunodeficiency Virus Type 1 Coreceptor Switching
Pastore, C., Ramos, A. G., & Mosier, D. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.14.7565-7574.2004 · Cited by 128
Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR
Fouchier, R. A. M., Brouwer, M., Broersen, S., et al. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.4.906-911.1995 · Cited by 118
HIV-1 Coreceptor Usage, Transmission, and Disease Progression
Philpott, S. M. (2003) · Current HIV Research · doi:10.2174/1570162033485357 · Cited by 108
KOOT, M., van Leeuwen, R., de Goede, R. E. Y., Keet, I. P. M., Danner, S. A., Schattenkerk, J. K. M. E., Reiss, P., Tersmette, M., Lange, J. M. A., & Schuitemaker, H. (1999) · The Journal of Infectious Diseases · doi:10.1086/314539 · Cited by 104
Brumme, Z. L., Dong, W. W. Y., Yip, B., Wynhoven, B., Hoffman, N. G., Swanstrom, R. I., Jensen, M. A., Mullins, J. I., Hogg, R. S., Montaner, J. S. G., et al. (2004) · AIDS · doi:10.1097/00002030-200403050-00001 · Cited by 94
Male circumcision and susceptibility to HIV infection among men in Tanzania
Urassa, M., Todd, J., Boerma, J. T., Hayes, R., & Isingo, R. (1997) · AIDS · doi:10.1097/00002030-199701000-00011 · Cited by 77
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy
Philpott, S. M., Weiser, B., Anastos, K., Ramirez, C. M., Robison, E., Meyer, W. A., Sacks, H. S., Mathur‐Wagh, U., Brunner, C., & Burger, H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11526 · Cited by 75
Grivel, J., Penn, M. L., Eckstein, D. A., Schramm, B., Speck, R. F., Abbey, N. W., HERNDIER, B. G., Margolis, L. B., & Goldsmith, M. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.11.5347-5351.2000 · Cited by 73
Harrowe, G., & Cheng‐Mayer, C. (1995) · Virology · doi:10.1006/viro.1995.1367 · Cited by 66
Prospects of HIV‐1 entry inhibitors as novel therapeutics
Pierson, T. C., Doms, R. W., & Pöhlmann, S. (2004) · Reviews in Medical Virology · doi:10.1002/rmv.435 · Cited by 60
Peptide-binding G protein-coupled receptors: new opportunities for drug design
Gurrath, M. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013371798 · Cited by 57 · cited 1×
“, desloratadine, ranitidine, and tegaserod) (16).”
Singh, A., & Collman, R. G. (2000) · Journal of Virology · doi:10.1128/jvi.74.21.10229-10235.2000 · Cited by 53
Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations
Skrabal, K., Trouplin, V., Labrosse, B., Obry, V., Damond, F., Hance, A. J., Clavel, F., & Mammano, F. (2003) · AIDS · doi:10.1097/00002030-200304110-00005 · Cited by 45
Dejucq‐Rainsford, N., Simmons, G., & Clapham, P. R. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-12-2899 · Cited by 33
Cited by
HIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
The design of drugs for HIV and HCV
Clercq, E. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2424 · Cited by 430
Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
Fätkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I. M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803154 · Cited by 364
Self-citationWhitcomb, J. M., Huang, W., Fransen, S., Limoli, K., Toma, J., Wrin, T., Chappey, C., Kiss, L. D. B., Paxinos, E. E., & Petropoulos, C. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00853-06 · Cited by 356
Self-citationWestby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P., Ciaramella, G., & Perros, M. (2007) · Journal of Virology · doi:10.1128/jvi.02006-06 · Cited by 350
Self-citation
Metadata
- Authors
- Westby, M., Lewis, M., Whitcomb, J., Youle, M., Pozniak, A. L., James, I. T., Jenkins, T. M., Perros, M., & van der Ryst, E.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2006-05-15
- Volume
- 80
- Issue
- 10
- Pages
- 4909-4920
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2119951120
- Cited by
- 337
- References
- 38
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.